美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物科技指数ETF-iShares Nasdaq

204.26

-2.2300-1.08%

盘前：205.180.9200+0.45%04:45 EDT

成交量：115.73万

成交额：2.37亿

市值：107.13亿

市盈率：32.36

高：206.93

开：206.85

低：203.92

收：206.49

52周最高：217.12

52周最低：149.09

股本：5,245.00万

流通股本：5,245.00万

量比：0.50

换手率：2.21%

股息：0.35

股息率：0.17%

每股收益(TTM):6.31

每股收益(LYR):35.34

净资产收益率：24.54%

总资产收益率：0.10%

市净率：1.32

市盈率(LYR):5.78

数据加载中...

总览公司新闻资讯公告

对外授权交易总额约1100亿美元！2026年上半年创新药“出海”观察：多款获批生物类似药寄望海外收入超越国内

每日经济新闻

松江奇迹：一家中国药企的“体系化出海”豪赌｜未来企业调研行

华夏时报网

阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。

复星医药(600196.SH)子公司地舒单抗生物类似药HLX14注册申请获受理

又爆了！集体飙涨！中东，再传重磅

对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药

对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药

全球118款生物药即将失去专利或独占权，生物类似药的“泼天富贵”来了？

安进（AMGN）联合疗法III期临床达主要终点

安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率

市场风向标：安进股价遭受重创

Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费

Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段

Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利

Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权

安进股价或创二十余年来最大单日跌幅

福泰制药(VRTX)股票9月8日盘中下跌3.06%：投资者必看的核心信息

TradingKey中文

吉利德科学(GILD)股票9月8日盘中下跌3.26%：释放什么信号？

TradingKey中文

诺华公司一款降胆固醇药物在临床试验中失败，Royalty Pharma股价下跌

安进(AMGN)股票9月8日盘中下跌8.33%：真相来了

TradingKey中文

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/IBB/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指数ETF-iShares Nasdaq","latestPrice":204.26,"timestamp":1791835200000,"preClose":206.49,"halted":0,"volume":1157283,"hourTrading":{"tag":"盘前","latestPrice":205.18,"preClose":204.26,"latestTime":"04:45 EDT","volume":38,"amount":7762.96566,"timestamp":1791881117402,"change":0.92,"changeRate":0.004504,"amplitude":0.005177},"delay":0,"changeRate":-0.010799554457843082,"floatShares":52450000,"shares":52450000,"eps":6.311863,"marketStatus":"盘前交易","change":-2.23,"latestTime":"10-13 05:01:22 EDT","open":206.85,"high":206.93,"low":203.92,"amount":237090797.56701,"amplitude":0.014577,"askPrice":205.77,"askSize":127,"bidPrice":204.31,"bidSize":300,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":204.26,"sharesOutstanding":49450000,"nav":206.296467,"aum":10840879340.85,"dividendRate":0.0017,"bidAskSpread":0.000349,"preHourTrading":{"tag":"盘前","latestPrice":205.18,"preClose":204.26,"latestTime":"04:45 EDT","volume":38,"amount":7762.96566,"timestamp":1791881117402,"change":0.92,"changeRate":0.004504,"amplitude":0.005177},"postHourTrading":{"tag":"盘后","latestPrice":204.26,"preClose":204.26,"latestTime":"19:47 EDT","volume":10034,"amount":2049515.9148,"timestamp":1791848828793,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.5014370891255452,"impliedVol":0.2474,"impliedVolPercentile":0.704},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":52450000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":0.5014370891255452,"shares":52450000,"dividePrice":0.3472,"high":206.93,"amplitude":0.014577,"preClose":206.49,"low":203.92,"week52Low":149.0909,"pbRate":"1.32","psRate":"257.76","week52High":217.12,"institutionHeld":0,"latestPrice":204.26,"committee":0.405152,"eps":6.311863,"divideRate":0.0017,"volume":1157283,"delay":0,"ttmEps":6.311863,"open":206.85,"prevYearClose":168.77,"prevWeekClose":206.49,"prevMonthClose":210.53,"prevQuarterClose":210.53,"fiveDayClose":207.96,"twentyDayClose":204.6,"sixtyDayClose":189.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-07-02","value":0.15606,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667660668","title":"对外授权交易总额约1100亿美元！2026年上半年创新药“出海”观察：多款获批生物类似药寄望海外收入超越国内","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","LU2272731782.SGD","IBB","IE00B5TLWC47.USD","XPH","LU1992135472.HKD","BK1161","MEDX","PPH","06978","LU1992135399.USD","LU2322448957.HKD","LU2473716301.USD","LU2322448791.USD","LU2272731600.USD","IBBQ","LU2272731865.HKD","BK1574","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666503466","title":"松江奇迹：一家中国药企的“体系化出海”豪赌 ｜ 未来企业调研行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666503466","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666503466?lang=zh_cn&edition=fundamental","pubTime":"2026-09-12 12:14","pubTimestamp":1789186482,"startTime":"0","endTime":"0","summary":"编者按：9月的一天，《华夏时报》未来企业竞争力调研团队来到位于上海松江的复宏汉霖全球生产基地——中国生物制药版图上，一处正在悄悄改写规则的所在。这家中国生物药企拒绝只卖“青苗”，而是试图用生物类似药的现金流，搭建从临床、报批到商业化的全球闭环。但真正的考验在于：创新药管线能否在专利悬崖窗口期兑现为第二增长曲线。上海松江，文俊路618弄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872706781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872706781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4588","IE00B5TLWC47.USD","LU1992135399.USD","LU2272731865.HKD","LU2322448791.USD","LU2473716301.USD","PPH","LU2272731600.USD","BCG","IBB","LU1992135472.HKD","XPH","LU2322448957.HKD","LU2272731782.SGD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_cn&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BME","IYH","XPH","PBE","IEIH","MRNY","IBB","RXL","LU1992135472.HKD","PPH","SBIO","BK4585","LU2473716301.USD","BK4588","WDNA","BBH","AZNH","GNOM","SYNB","IBRN","RSPH","LU1992135399.USD","BBP","LFSC","LU2322448791.USD","MRNX","PBPH","IE00B5TLWC47.USD","XBIX","LU2272731782.SGD","HELX","LU2322448957.HKD","PJP","CANC","BIOY","LU2272731600.USD","IEHS","MEDI","TMED","FTXH","LU2272731865.HKD","BIB","FBT","IDNA","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"复星医药(600196.SH)子公司地舒单抗生物类似药HLX14注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_cn&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK1515","LU2272731865.HKD","XPH","BK0175","IE00B5TLWC47.USD","BK0012","LU2322448957.HKD","LU2473716301.USD","BK1191","LU1992135472.HKD","LU2272731782.SGD","LU2272731600.USD","BK0187","LU1992135399.USD","IBB","LU2322448791.USD","PPH","BK4585","BK0096","600196","02196","BK1593","BK4588","BK0060","BK0196","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集体飙涨！中东，再传重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4588","BIB","LU2468319806.SGD","BK4534","AMGN","LU0122379950.USD","TBXU","LU0320765992.SGD","LU2089984988.USD","BK4581","BK4139","IE00BFTCPJ56.SGD","BK4566","BK4599","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4585","LU1057294990.SGD","BBH","LU1061106388.HKD","LU0889565916.HKD","LU0868494617.USD","IBBQ","IE00B4R5TH58.HKD","LU2242652126.USD","IE00BJT1NW94.SGD","PJP","IE00BJJMRZ35.SGD","LU1983299246.USD","LU0109394709.USD","PBE","IE00B2B36J28.USD","BK4533","IBB","IE0002141913.USD","LU0289739699.SGD","SG9999001440.SGD","LU1023059063.AUD","LU1571399168.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306685.HKD","HK0000165453.HKD","MEDX","LU2272731600.USD","LU1992135472.HKD","PPH","IBBQ","LU2322448957.HKD","IE00B5TLWC47.USD","06978","LU2272731865.HKD","02696","HK0000320223.HKD","BK1161","LNGR","BK4585","159992","XPH","LU2473716301.USD","HK0000320264.USD","LU2272731782.SGD","IBB","BK4588","BK1574","LU2322448791.USD","HK0000306701.USD","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XPH","IBBQ","LNGR","LU2272731600.USD","LU1992135399.USD","LU2322448791.USD","BK4588","PPH","LU2473716301.USD","LU2272731782.SGD","LU1992135472.HKD","MEDX","BK4585","IE00B5TLWC47.USD","LU2322448957.HKD","IBB","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580032","title":"全球118款生物药即将失去专利或独占权，生物类似药的“泼天富贵”来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580032","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580032?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954152,"startTime":"0","endTime":"0","summary":"中国市场中生物类似药面临集采降价的潜在压力，而市场的增长潜力在哪？9月8日，在复宏汉霖开放日活动上，波士顿咨询公司（BCG）合伙人杜菁表示，全球正迎来生物类似药发展的重大窗口期，重磅原研药集中进入专利悬崖，叠加欧美政策持续利好，预计2035年全球生物类似药市场规模将突破2400亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869495082.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869495082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731865.HKD","PPH","LU2473716301.USD","LU1992135399.USD","LU2272731782.SGD","LU2322448791.USD","BK4585","159839","LU1992135472.HKD","LU2322448957.HKD","IE00B5TLWC47.USD","XPH","IBB","BK4588","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安进（AMGN）联合疗法III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4566","LU2112291526.USD","AZN","LU2237443895.HKD","LU2468319806.SGD","IBB","LU0109394709.USD","LU2242646821.SGD","BK4581","LU1267930573.SGD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","TBXU","AZNH","BK4585","BK4599","BK4568","IBBQ","LU0868494617.USD","LU1023059063.AUD","LU0122379950.USD","IE00B4R5TH58.HKD","LU0708994859.HKD","LU2462157665.USD","LU0128525929.USD","LU2236285917.USD","LU2237443622.USD","LU1829250122.USD","AMGN","IE00B2B36J28.USD","PBE","LU2237443382.USD","LU2242652126.USD","PJP","LU0289739699.SGD","LU2456880835.USD","BBH","SG9999001440.SGD","BK4534","LU2237443978.SGD","BK4139","BIB","LU0432979614.USD","IE00BFTCPJ56.SGD","LU0029864427.USD","LU0058720904.USD","BK4533","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1057294990.SGD","BK4534","IE00BJJMRZ35.SGD","BBH","PBE","IBBJ","LU0320765992.SGD","BK4599","LU0122379950.USD","LU0889565916.HKD","LU0868494617.USD","BK4585","BMED","BIB","LU1983299246.USD","BK4581","PSYK","SG9999001440.SGD","MDTX","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","IBB","AMGN","IE00B2B36J28.USD","IBBQ","LU2112291526.USD","LU1023059063.AUD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","BK4566","LU0289739699.SGD","IE00BJT1NW94.SGD","PJP","LU2242646821.SGD","LU2242652126.USD","LU1061106388.HKD","LU2089984988.USD","LU2468319806.SGD","BK4533","TBXU","LU0109394709.USD","LU1571399168.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市场风向标：安进股价遭受重创","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","TBXU","PBE","LU2468319806.SGD","BK4599","IE0002141913.USD","IBB","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","BK4585","BK4581","BK4588","LU2112291526.USD","BK4566","BBH","IE00B2B36J28.USD","LU0868494617.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4534","LU0109394709.USD","LU0889565916.HKD","BK4139","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU2089984988.USD","AMGN","PJP","LU1571399168.USD","LU0122379950.USD","LU1983299246.USD","IBBQ","IE00B4R5TH58.HKD","LU1057294990.SGD","SG9999001440.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU2242646821.SGD","BIB","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望获得高达2.8亿美元里程碑付款及美国境外特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU0889565916.HKD","BMED","GILD","IE00B19Z3581.USD","BK4568","IE0002270589.USD","LU1066051498.USD","LU1934455277.USD","BBH","BIB","LU1037948897.HKD","IE00BKVL7J92.USD","LU2357627491.SGD","LU2468319806.SGD","LU0823416689.USD","SG9999015986.USD","SG9999015952.SGD","BK4578","IE00BZ1G4Q59.USD","LU1571399168.USD","LU1674673691.USD","LU2089984988.USD","SG9999015978.USD","TMED","LU0965509010.AUD","LU1430594728.SGD","LU1934455194.USD","MEDI","BK4588","IE00B7SZLL34.SGD","LU0320765992.SGD","LU0861579265.USD","LU1674673428.USD","BK4585","SG9999015945.SGD","BK4583","LU0109394709.USD","LU1023059063.AUD","ASMB","LU1839511570.USD","LU1037948541.HKD","LU1057294990.SGD","BK4532","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU0114720955.EUR","LU2087621335.USD","LU0965509101.SGD","LU1585245621.USD","LU0289739699.SGD","LU1934455863.HKD","IBBQ","LU0234570918.USD","IE00B19Z3B42.SGD","BK4139","BK4566","BK4550","IE00BSNM7G36.USD","IE00B3T34201.USD","LU0882574055.USD","LU0965509283.SGD","LU1066053197.SGD","LU2112291526.USD","LU0859254822.USD","LU0965508806.USD","TBXU","LU1778281490.HKD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179预计2026年底前将推进至生殖器疱疹二期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","BIB","IE00B3T34201.USD","LU0889565916.HKD","LU1066053197.SGD","LU1674673691.USD","BMED","LU1023059063.AUD","BK4139","LU1934455863.HKD","LU0122379950.USD","LU0823416689.USD","LU0965508806.USD","LU2324357040.USD","MEDI","LU0859254822.USD","LU0965509010.AUD","LU2468319806.SGD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00BSNM7G36.USD","SG9999015952.SGD","LU2087621335.USD","LU1839511570.USD","LU0882574055.USD","LU1037948541.HKD","SG9999015978.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4578","IE0002270589.USD","TMED","LU1061106388.HKD","BK4568","LU0058720904.USD","LU1057294990.SGD","LU1571399168.USD","BK4550","BK4583","GILD","LU1778281490.HKD","BK4588","LU1066051498.USD","LU0861579265.USD","LU1934455277.USD","LU0320765992.SGD","LU0234570918.USD","SG9999015945.SGD","LU1934455194.USD","IE00B19Z3581.USD","LU1585245621.USD","BK4532","BBH","LU2089984988.USD","LU2357627491.SGD","LU0114720955.EUR","IBBQ","LU1674673428.USD","IE00BKVL7J92.USD","LU1037948897.HKD","LU0965509283.SGD","LU0109394709.USD","BK4566","IBB","BK4585","TBXU","ASMB","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德独享HSV HPI项目临床开发与商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU0823416689.USD","IBB","LU1061106388.HKD","LU0109394709.USD","LU1778281490.HKD","BK4566","LU1571399168.USD","LU1934455863.HKD","LU0320765992.SGD","LU1934455194.USD","LU1674673428.USD","SG9999015952.SGD","BMED","LU1674673691.USD","IE00BSNM7G36.USD","LU1430594728.SGD","TBXU","LU0965509101.SGD","LU1934455277.USD","BK4550","LU0965509283.SGD","LU0889565916.HKD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU2357627491.SGD","SG9999015986.USD","LU2112291526.USD","IE00BKVL7J92.USD","IE0002270589.USD","LU2468319806.SGD","BK4585","SG9999015978.USD","BK4139","IE00B19Z3581.USD","LU1057294990.SGD","BK4532","LU1066053197.SGD","LU0882574055.USD","LU0122379950.USD","LU1066051498.USD","BIB","LU2087621335.USD","LU2324357040.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","TMED","LU0058720904.USD","LU1023059063.AUD","LU1037948897.HKD","ASMB","LU0114720955.EUR","LU1585245621.USD","BBH","BK4588","GILD","SG9999015945.SGD","LU0965508806.USD","BK4578","MEDI","LU0289739699.SGD","BK4583","LU0861579265.USD","LU0859254822.USD","LU2089984988.USD","IBBQ","BK4568","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使与吉利德关于HSV解旋酶-引物酶抑制剂项目的美国利润分成选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509101.SGD","LU1674673428.USD","LU1839511570.USD","SG9999015986.USD","TBXU","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU2468319806.SGD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","IBB","IE00BSNM7G36.USD","ASMB","BK4583","LU0058720904.USD","LU0234570918.USD","LU0289739699.SGD","LU0320765992.SGD","LU2324357040.USD","LU1934455194.USD","BK4585","BK4588","LU2112291526.USD","BBH","BK4566","LU0882574055.USD","SG9999015952.SGD","LU1037948541.HKD","LU0965508806.USD","LU0965509010.AUD","IE00B3T34201.USD","BK4550","IE00BKVL7J92.USD","LU1037948897.HKD","SG9999015978.USD","LU1585245621.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","BK4139","BK4568","BMED","LU1023059063.AUD","IE00B19Z3581.USD","LU1430594728.SGD","LU2089984988.USD","LU1934455277.USD","LU2087621335.USD","IE0002270589.USD","LU0122379950.USD","LU1571399168.USD","IBBQ","LU0861579265.USD","LU0965509283.SGD","LU1066053197.SGD","LU1057294990.SGD","LU1061106388.HKD","BK4532","LU2357627491.SGD","LU1934455863.HKD","MEDI","BK4578","LU0859254822.USD","SG9999015945.SGD","TMED","BIB","LU1674673691.USD","GILD","LU0823416689.USD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安进股价或创二十余年来最大单日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"us","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1983299246.USD","BK4599","LU0058720904.USD","BBH","04332","IE00BFTCPJ56.SGD","BK4588","IE0002141913.USD","AMGN","IE00B2B36J28.USD","LU2242646821.SGD","PJP","LU2242652126.USD","LU2468319806.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4533","IBB","BK4566","BK4585","TBXU","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","IBBQ","LU1061106388.HKD","LU2089984988.USD","SG9999001440.SGD","LU0889565916.HKD","LU1571399168.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","BK4534","PBE","LU0320765992.SGD","BK4139","LU1023059063.AUD","LU0868494617.USD","BK4581","LU0289739699.SGD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374214","title":"福泰制药(VRTX)股票9月8日盘中下跌3.06%：投资者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374214","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374214?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 02:16","pubTimestamp":1788891392,"startTime":"0","endTime":"0","summary":"• Vertex 股价在反弹至接近52周高点后遭遇波动与获利回吐。\n• 对 Crinetics 的收购整合要到2029年才能实现非GAAP增盈。\n• 技术指标显示 MACD 呈中性，RSI 呈中性，威廉指标（Williams %R）呈超卖状态。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156640-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU0061475181.USD","LU1585245621.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4533","IBBQ","IE0009355771.USD","LU2089984988.USD","LU2237438978.USD","BIB","IE00BJT1NW94.SGD","SG9999013999.USD","LU0432979614.USD","LU2362541273.HKD","LU0234570918.USD","LU1674673428.USD","BK4585","IE0002141913.USD","BK4532","LU1069344957.HKD","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","IE0002270589.USD","LU0889565916.HKD","SG9999001176.SGD","SGXZ57979304.SGD","BK4139","LU2417539215.USD","LU0417517546.SGD","BK4588","IDNA","LU1674673691.USD","LU1093756168.USD","LU2362541513.USD","SG9999001176.USD","LU2362540622.SGD","PBE","VRTX","LU1093756325.SGD","LU0256863811.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科学(GILD)股票9月8日盘中下跌3.26%：释放什么信号？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU0114720955.EUR","LU1839511570.USD","SG9999015952.SGD","LU0882574055.USD","LU0122379950.USD","LU1037948541.HKD","IE00B19Z3581.USD","LU0320765992.SGD","LU1674673428.USD","BIB","IE00B7SZLL34.SGD","LU0861579265.USD","IBB","LU2324357040.USD","LU0058720904.USD","LU0289739699.SGD","LU1023059063.AUD","LU1674673691.USD","LU1571399168.USD","GILD","IE0002270589.USD","BBH","BK4578","LU1430594728.SGD","LU0823416689.USD","LU2112291526.USD","BK4585","MEDI","SG9999015986.USD","BK4583","LU1778281490.HKD","SG9999015945.SGD","LU0109394709.USD","IE00BSNM7G36.USD","SG9999015978.USD","TBXU","IE00B3T34201.USD","LU0965509101.SGD","LU1934455277.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0965508806.USD","BK4568","IBBQ","TMED","LU2087621335.USD","BK4532","BMED","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"诺华公司一款降胆固醇药物在临床试验中失败，Royalty Pharma股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","AMGN","BBH","IBBQ","BK4585","IHE","LU1061106388.HKD","LU0058720904.USD","LU2112291526.USD","LU2242652126.USD","LU0109394709.USD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4139","IE00B2B36J28.USD","LU0868494617.USD","PBE","BK4588","IE0009355771.USD","BK4581","LU0889565916.HKD","IE00BJT1NW94.SGD","SG9999001440.SGD","BIB","LU0289739699.SGD","IBB","LU1571399168.USD","BK4007","BK4533","LU1057294990.SGD","BK4599","BK4566","LU0320765992.SGD","IONS","LU1023059063.AUD","LU1983299246.USD","RPRX","LU2242646821.SGD","BK4534","IE00BFTCPJ56.SGD","LU0122379950.USD","PJP","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376637","title":"安进(AMGN)股票9月8日盘中下跌8.33%：真相来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376637","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376637?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 22:16","pubTimestamp":1788876978,"startTime":"0","endTime":"0","summary":"• 诺华 pelacarsen 试验失败，加大了安进竞品 olpasiran 的临床不确定性。\n• 出于对估值的担忧，BMO Capital 将安进的评级从“跑赢大盘”下调至“与大盘持平”。\n• 技术指标显示，安进的 RSI 为 40.256，威廉指标（Williams %R）为 97.857。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156239-market-movers-amgn-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","PBE","LU1057294990.SGD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU1571399168.USD","IE0009355771.USD","BK4599","LU0868494617.USD","BK4533","BK4585","AMGN","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","LU2112291526.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","PJP","BK4534","IBB","LU0058720904.USD","LU2242646821.SGD","BK4588","BK4581","BBH","BK4566","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}